Client News

Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)

AFYREN obtains FSSC22000 certification for its AFYREN NEOXY plant, recognizing excellence in food safety quality

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

PL BioScience Signs Exclusive Japanese Distribution Agreement with Summit Pharmaceuticals International

Andera Partners strengthens its position among the leading players in private equity

Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program

PL BioScience Wins Regulatory Certification from Japan’s PMDA

Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board

Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region